Coherus Oncology enters ATM offering to sell up to $50M of common stock

Coherus Oncology, Inc.

Sales agreement dated Aug 28, 2026 with Leerink Partners LLC for at-the-market sales of common stock.
Company may offer up to $50.0M aggregate gross proceeds; no obligation to sell any shares.
Agent commission up to 3% of gross proceeds; customary indemnification provided.
Proceeds intended for general corporate purposes including working capital.
Offered under S-3 shelf (effective Dec 8, 2025) with prospectus supplement filed Aug 28, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.